Advancing hope for those facing mantle cell lymphoma.
Supporting patients.
Funding research.
Accelerating the path to a cure.
The Mantle Cell Lymphoma Alliance supports those facing mantle cell lymphoma with trusted information and expert-guided support. We connect patients, caregivers, researchers, and oncologists across all clinical settings to improve outcomes and expand access to care. We support targeted research that advances progress toward better treatments and ultimately a cure.
What We Do
Three pillars guiding our mission to transform outcomes for those affected by MCL.
Advancing Research
We fund and support targeted research that moves us closer to better treatments and ultimately a cure for mantle cell lymphoma.
Trusted Education & Access
We provide clear, medically reviewed information and connect patients with the specialists and resources they need.
Collaboration & Community
We bring together patients, caregivers, researchers, and clinicians to share knowledge and build a stronger MCL community.
We Remember
You may not remember much of what the doctor said after that. Many of us don't.
- You may have only read your pathology report and haven't even talked to the doctor.
- You may be sitting in your car staring at the steering wheel.
- You may be awake at 3 a.m. searching the internet.
- You may be trying to figure out how to tell your spouse, your children, your parents, your friends, or your employer.
You may be wondering:
- Am I going to die?
- How much time do I have?
- How do I tell my family?
- Why did this happen to me?
- Did I miss symptoms?
- Should I get a second opinion?
- Where do I find a specialist?
- What treatment will I need?
- What if I make the wrong decision?
- How am I supposed to learn all of this?
If those thoughts are racing through your mind, you are not alone.
Many of us remember hearing the words "mantle cell lymphoma" and immediately going to Google.
Many of us found frightening statistics and assumed the worst.
Most of us cried.
Most of us were convinced our lives would never be the same.
And in some ways, they won't be.
But before you go any further, there is something we want you to know:
- You do not need to solve this today.
- You do not need to learn every treatment.
- You do not need to understand every test result.
- You do not need to make every decision right now.
Today, your job is simply to take the next step.
That's all. One step. Then another. And another.
That's how all of us got through those first days.
MCL by the Numbers
Understanding the scope of mantle cell lymphoma.
Statistics sourced from published medical literature including the American Cancer Society and the Leukemia & Lymphoma Society.
Stories, updates, and expert guidance from the MCL community.
Keep up with the newest MCLA articles, research updates, and community news.
CARiBOU Regimen in First-Line MCL
CARiBOU Regimen Shows High Response Rates in Newly Diagnosed MCL
In a phase 2 study of 41 previously untreated, fit patients with MCL, the CARiBOU regimen — lower-dose cytarabine combined with the BTK inhibitor acalabrutinib (Calquence) and other established MCL treatments — produced a 90% complete metabolic response rate.
A September to Remember: Together, We Made MCL Seen!
A September to Remember: Together, We Made MCL Seen!
Throughout Blood Cancer Awareness Month and on World Lymphoma Awareness Day, our community shared stories, exceeded our fundraising goal, and helped make mantle cell lymphoma seen. Thank you!
Acalabrutinib + BR in First-Line MCL
Long-Term Study Results Reinforce Benefit of Acalabrutinib in First-Line MCL Treatment
Five-year results from the phase 3 ECHO trial, presented at the 2026 SOHO Annual Meeting, show that adding acalabrutinib (Calquence) to bendamustine and rituximab kept MCL from progressing for a median of 72.5 months in adults 65 and older, compared with 47.8 months with BR alone.
Stay Informed. Join Our Community.
Receive the latest updates on MCL research, patient resources, and community events delivered to your inbox.